Evaluating Piezo-ICSI. - The EPI Study.
Launched by VITROLIFE · Dec 9, 2020
Trial Information
Current as of July 01, 2025
Suspended
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients receiving controlled ovarian stimulation with gonadotrophins needing ICSI for fertilizing oocytes.
- • 2. Availability of at least six mature oocytes (MII) after oocyte pick-up.
- • 3. Planned blastocyst culture.
- Exclusion Criteria:
- • 1. Intention to perform any form of preimplantation genetic testing
- • 2. The use of IMSI or polarized light in the ICSI process
- • 3. The use of assisted hatching prior to randomization.
- • 4. Surgical sperm retrieval (SSR) patients.
- • 5. Previous participation in this RCT
- • 6. Concurrent participation in another investigation that can affect the primary outcome of this study.
- • 7. Sperm sample with \<0.1million/ml or motility of \<2% after preparation.
- • 8. Fertility preservation cycles.
- • 9. If a day 2-4 transfer is planned
- • 10. Use of vitrified oocytes.
About Vitrolife
Vitrolife is a leading global company dedicated to advancing reproductive medicine and improving outcomes in assisted reproduction. With a strong focus on innovation and quality, Vitrolife develops and provides a comprehensive range of products and services, including culture media, cryopreservation solutions, and laboratory equipment, aimed at enhancing the efficiency and effectiveness of fertility treatments. Committed to supporting healthcare professionals and patients alike, Vitrolife actively engages in clinical research and trials to ensure the continuous improvement of reproductive technologies and to foster successful reproductive outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, , United Kingdom
Oxford, , United Kingdom
Patients applied
Trial Officials
Scott Nelson, MD, PhD
Principal Investigator
University of Glasgow
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials